Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE is a phase 3 interventional study registered as NCT03673943 by Radiomedix, Inc., with 63 participants recorded, started 2018-08-23 and reaching its primary completion in 2019-03-23. Interventions recorded: 64Cu-DOTATATE. Conditions recorded: Neuroendocrine Tumors.

Linked to the technology Somatostatin receptor PET because the registry names it ("64cu dotatate") among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.